STOCKHOLM, March 6, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

斯德哥尔摩，2024年3月6日/PRNewswire/--Medivir AB（纳斯达克-斯德哥尔摩：MVIR）是一家专注于在医疗需求高度未满足的领域开发癌症创新治疗方法的制药公司，宣布该公司将参加2024年3月7日的瑞士-北欧生物会议。

CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

首席执行官延斯·林德伯格（Jens Lindberg）将向Medivir介绍正在进行的福斯特罗西他滨-布拉帕胺（fostrox）1b/2a期临床研究的数据，以及这些数据如何加速fostrox的开发计划。

Swiss Nordic Bio aims to bring together biotech, pharma and life science investors from Switzerland and the Nordic region. In addition to the presentation, the company will also conduct a number of 1-1 meetings with potential investors and partners.

瑞士北欧生物旨在汇集瑞士和北欧地区的生物技术、制药和生命科学投资者。除了演讲之外，该公司还将与潜在投资者和合作伙伴举行多次1-1会议。

After the meeting, the presentation will also be available on Medivir's website www.medivir.se.

会议结束后，演示文稿也将在Medivir的网站www.Medivir.se上发布。

For additional information, please contactMagnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.com

有关更多信息，请联系Medivir Ab首席财务官Magnus Christensen电话：+46 8 5468 3100电子邮件：magnus.christensen@medivir.com

Medivir in brief

Medivir简介

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects.

Medivir开发创新药物，重点关注未满足医疗需求的癌症。候选药物针对可用疗法有限或缺失的适应症领域，并且有很大的机会为患者提供显着改善。Medivir专注于开发福斯特罗西他滨-布拉帕胺（fostrox），这是一种专为选择性治疗肝癌和减少副作用而设计的前药。

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com. .

合作和伙伴关系是Medivir商业模式的重要组成部分，药物开发由Medivir或合伙进行。Medivir的股票（股票代码：MVIR）在纳斯达克斯德哥尔摩的小盘股名单上上市。www.medivir.com。

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/652/3941422/2650494.pdf

https://mb.cision.com/Main/652/3941422/2650494.pdf

Press release (PDF)

新闻稿（PDF）

SOURCE Medivir

来源Medivir